Drugs / TRX-221
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06186076 | Jun 2024 → Dec 2025 | non-small cell lung carcinoma | Therapex Co., Ltd | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRX-221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06186076 ↗ |
| Route | Oral | “TRX-221 oral dose as defined” NCT06186076 ↗ |